Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL)

Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch, Claudia Haferlach, Stefan Kubicek, Marius Mayerhoefer, Georg Hopfinger, Ulrich Jaeger and Claire Dearden


T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of T-PLL patients it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG)set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL and will thus support clinical decision making as well as the approval of new therapeutics by healthcare authorities.

  • Submitted March 2, 2019.
  • Revision received July 9, 2019.
  • Accepted June 26, 2019.